Will Theranos get more than 100 FDA approvals for blood tests by the end of 2018?

Your submission is now in Draft mode. Once it's ready, please submit your draft for review by our team of Community Moderators. Thank you!


Medical testing and devices company Theranos has recently come into controversy after a Wall Street Journal article asserted that it has over-promised and under-delivered on its testing suite.

As summarized by The Washington Post,

Theranos, once valued at $9 billion based on its immense promise to make blood testing cheaper and more efficient, has been embroiled in questions about its technology and regulatory strategy for months. The scrutiny was sparked by a Wall Street Journal investigation that revealed that the intensely secret company's much-touted fingerprick blood tests were barely being used and employees had raised questions about the accuracy of its tests.

In response, Theranos itself claims:

Our proprietary devices are making it possible to run finger-stick samples for tests that could never be run on finger-stick before. We began using our proprietary devices in our lab at the launch of our retail operations. And we initiated filings with FDA two years ago—by choice, not necessity—because we are seeking to create a new model for laboratory testing standards, and have championed FDA oversight ever since. It is the right thing, which is also the hard thing. [...]

Capabilities of Theranos' devices: The article implies that Theranos' proprietary devices were only capable of running a limited number of tests. First, "Edison" is only one of many proprietary devices used as part of Theranos proprietary technologies. In total, Theranos research and development has developed hundreds of tests for finger-stick samples using our proprietary devices. [...]

Theranos' filings with FDA show the versatility of Theranos devices, and our confidence in the results of our tests: Theranos has publicly advocated for FDA regulation of laboratory-developed tests (LDTs), and over 120 of the tests developed for use on our devices used as part of Theranos proprietary technologies have been submitted in pre-submissions to FDA.

Will Theranos succeed in getting 100 or more tests approved by the end of 2018?

Question will be resolved per announcement by Theranos or in a major media article.

Make a Prediction


Note: this question resolved before its original close time. All of your predictions came after the resolution, so you did not gain (or lose) any points for it.

Note: this question resolved before its original close time. You earned points up until the question resolution, but not afterwards.

This question is not yet open for predictions.

Current points depend on your prediction, the community's prediction, and the result. Your total earned points are averaged over the lifetime of the question, so predict early to get as many points as possible! See the FAQ.

Metaculus help: Predicting

Predictions are the heart of Metaculus. Predicting is how you contribute to the wisdom of the crowd, and how you earn points and build up your personal Metaculus track record.

The basics of predicting are very simple: move the slider to best match the likelihood of the outcome, and click predict. You can predict as often as you want, and you're encouraged to change your mind when new information becomes available.

The displayed score is split into current points and total points. Current points show how much your prediction is worth now, whereas total points show the combined worth of all of your predictions over the lifetime of the question. The scoring details are available on the FAQ.

Thanks for predicting!

Your prediction has been recorded anonymously.

Want to track your predictions, earn points, and hone your forecasting skills? Create an account today!

Track your predictions
Continue exploring the site